Form 4: BioAge CFO Exercises Options, Sells Shares

BioAge Labs' Chief Financial Officer, Dov A. Goldstein, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged trading plan.

Summary

• Dov A. Goldstein, Chief Financial Officer of BioAge Labs, Inc. (BIOA), executed transactions on January 13, 2026, under a Rule 10b5-1 trading plan adopted on December 2, 2024.
• Mr. Goldstein exercised stock options to acquire 27,000 shares of common stock at an exercise price of $8.39 per share.
• Immediately following the option exercise, Mr. Goldstein sold a total of 27,000 shares of common stock in multiple transactions.
• The sales occurred at weighted average prices ranging from $18.4278 to $21.0808 per share.
• Specifically, 8,974 shares were sold at $18.4278, 4,440 shares at $19.4526, 11,663 shares at $20.5392, and 1,923 shares at $21.0808.
• Following these transactions, Mr. Goldstein directly beneficially owns 22,408 shares of common stock and 92,587 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction (option exercise and sale) under a Rule 10b5-1 plan, which typically does not carry strong positive or negative implications for the company's operational performance or future prospects.

Positives

• The Chief Financial Officer realized a significant profit by exercising options at $8.39 and selling the shares at prices ranging from $18.4278 to $21.0808.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and non-opportunistic approach to insider trading.

Negatives

• The sale of shares by a key executive, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence, although this is often a routine liquidity event.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may observe the Chief Financial Officer's decision to sell shares, but the execution under a Rule 10b5-1 plan generally mitigates concerns about opportunistic insider trading, suggesting a pre-planned liquidity event rather than a reaction to new, undisclosed information.

Key Dates

Recommendation

The filing details a pre-scheduled insider transaction (option exercise and sale) by the CFO under a Rule 10b5-1 plan. While insider selling occurred, the pre-planned nature reduces negative implications. This transaction alone does not provide sufficient new information to alter a fundamental investment thesis for BioAge Labs, warranting a 'hold' recommendation based solely on this filing.

Keywords

BioAge Labs, BIOA, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Dov A. Goldstein, CFO, 10b5-1 Plan